Dr. Steensma is Professor of Medicine at Harvard Medical School and Attending Physician at Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, Massachusetts. His primary area of clinical activity and research focus is myelodysplastic syndromes (MDS) and related conditions, and he was honored for his focus on the development of new therapies and discovery of new somatic genetic mutations critical to understanding the pathobiology of myeloid neoplasms.
Dr. Steensma is a Fellow of the American College of Physicians, and a member of the American Society of Hematology, the American Society of Clinical Oncology, the European Hematology Association, and the Alpha Omega Alpha medical honor society. He is a member of the editorial board of 5 journals, including the Journal of Clinical Oncology, Leukemia Research, and Haematologica, and has more than 150 publications in peer-reviewed journals including Blood, Lancet, the Journal of Clinical Oncology, and Leukemia. His laboratory and clinical research has been funded by the National Cancer Institute and by several philanthropic groups. His primary clinical and research focus is myelodysplastic syndromes, and he also maintains an active interest in non-malignant hematology, especially disorders of red cells and therapy of cancer-associated anemia.